Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas.
BACKGROUND
Craniopharyngioma is a rare, benign epithelial brain tumor of the suprasellar region with a high rate of recurrence. Clinical and histopathological features that might be predictors of recurrence/regrowth have not been clearly delineated.


METHODS
We compared recurrence/regrowth of the tumors with the clinico-pathological characteristics, vascular density, cell proliferation index, and immunohistochemical profile (cytokeratins, epithelial membrane antigen [EMA], carcinoembrionary antigen [CEA], and laminin) of 47 patients with craniopharyngioma followed for more than 5 years.


RESULTS
Tumors were adamantinomatous in 42 cases (89%) and papillary squamous in 5 cases (11%). Immunoreactivity for cytokeratin 8/18/19 was positive in 64%; cytokeratin 5 in 42%; laminin 8 in 62%; and CEA in 21%. The cell proliferation index and vascular density were greater in adamantinomatous than in papillary tumors (22+/-6 versus 17+/-3, p=0.05; and 21+/-3 versus 17+/-3, p=0.037, respectively); they were neither related to recurrence nor to regrowth. No significant differences were found between adamantinomatous and papillary tumors regarding the presence of cytokeratin, laminin, CEA or glial fibrillary acidic protein (GFAP). Recurrence rate at 5 years was 59%. No relation was found between recurrence and adjuvant radiotherapy (AR). Residual tumor after surgery, whorl-like arrays (p=0.04) and immunoreactivity for p53 (p=0.022) were significantly related to recurrence/regrowth.


CONCLUSIONS
Residual tumor after surgery, immunoreactivity to p53 and presence of whorl-like arrays are associated to recurrence/regrowth of craniopharyngioma.
Tena-Suck
Martha Lilia
ML
Department of Neuropathology, Instituto Nacional de Neurología y Neurocirugía, Mexico.
Salinas-Lara
Citlaltepetl
C
Arce-Arellano
Rosa Isela
RI
Rembao-Bojórquez
Daniel
D
Morales-Espinosa
Daniela
D
Sotelo
Julio
J
Arrieta
Oscar
O
D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000503:physiopathology*; D002272:Carcinoembryonic Antigen / Q000378:metabolism; D049109:Cell Proliferation; D003397:Craniopharyngioma / Q000175:diagnosis* / Q000378:metabolism / Q000503:physiopathology*; D004847:Epithelial Cells / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000378:metabolism; D007797:Laminin / Q000378:metabolism; D008297:Male; D018396:Mucin-1 / Q000378:metabolism; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000532:radiotherapy / Q000601:surgery; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D011237:Predictive Value of Tests; D011379:Prognosis; D011878:Radiotherapy / Q000706:statistics & numerical data; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D007797:Laminin; D018396:Mucin-1; D016159:Tumor Suppressor Protein p53; D007633:Keratins